Sequence Heterogeneity in NS5A of Hepatitis C Virus Genotypes 2a and 2b and Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy-Reference-Cited by-同舟云学术

Sequence Heterogeneity in NS5A of Hepatitis C Virus Genotypes 2a and 2b and Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy

Published:2012-02-02 Issue:2 Volume:7 Page:e30513
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

El-Shamy Ahmed,Shoji Ikuo,Kim Soo-Ryang,Ide Yoshihiro,Imoto Susumu,Deng Lin,Yoon Seitetsu,Fujisawa Takashi,Tani Satoshi,Yano Yoshihiko,Seo Yasushi,Azuma Takeshi,Hotta Hak

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.;JM Micallef;J Viral Hepat,2006

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.;MW Fried;N Engl J Med,2002

3. Response-guided telaprevir combination treatment for hepatitis C virus infection.;KE Sherman;N Engl J Med,2011

4. Boceprevir for chronic HCV genotype 1 infection.;AR Limaye;N Engl J Med,2011

5. There are two major types of hepatitis C virus in Japan.;N Enomoto;Biochem Biophys Res Commun,1990

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier;Biochemistry and Biophysics Reports;2022-12

2. Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes;International Journal of Molecular Sciences;2022-02-27

3. Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment;Journal of Virology;2017-05-15

4. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A;Journal of Hepatology;2015-10

5. The relationships betweenIFNL4genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3;Alimentary Pharmacology & Therapeutics;2015-06-01